Boston-based healthcare venture capital firm Omega Funds closed its seventh and largest fund with $650 million in capital commitments, handily beating its $500 million target on the back of strong support from new as well as existing limited partners. Omega Fund VII also significantly outpaced its predecessor, as Fund VI closed with $438 million in December 2019.
Omega said Fund VII is "stage-agnostic," meaning its investments will run the gamut from seed founding to early venture rounds and later-stage financings, albeit with a focus on companies in the U.S. and Europe.
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
Monthly
$30
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Annual
$300
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators
